September 4, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Synergetics USA Inc (NASDAQ:SURG), was announced concerning whether the takeover of Synergetics USA Inc. by Valeant Pharmaceuticals International is unfair to NASDAQ:SURG stockholders.

The investigation by a law firm concerns whether certain officers and directors of Synergetics USA Inc breached their fiduciary duties owed to NASDAQ:SURG investors in connection with the proposed acquisition.

On September 2, 2015, Synergetics USA Inc (NASDAQ:SURG) and Valeant Pharmaceuticals International (Valeant), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX), announced that they have entered into an agreement under which Valeant will acquire Synergetics USA Inc (NASDAQ:SURG) for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments of up to $1.00 per share if specified sales milestones are achieved following the closing.

However, the investigation concerns whether the offer is unfair to NASDAQ:SURG stockholders. More specifically, the investigation concerns whether the Synergetics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Synergetics USA Inc (NASDAQ:SURG) reported that ita Total Revenue rose from $62.80 million for the 12 months period that ended on July 31, 2013 to $64.77 million for the 12 months period that ended on July 31, 2014 and that its respective Net Income increased from $2.56 million to $3.06 million.